The ELIAS cancer immunotherapy (ECI ®) platform offers a completely new approach to cancer treatment. It is built upon 50+ years of intensive scientific and medical research into the interactions between cancer and the immune response. ECI utilizes a combination of cancer vaccination pretreatment and activated “killer” T cell immunotherapy
Cancer treatment with ECI involves the following sequential and dependent steps:
Apheresis is a medical technology in which the whole blood of the patient can be passed through a medical instrument that separates out a particular component, in this case T cells, so they can be removed for further processing.
Although every patient and every experience is unique, there is a basic timeframe for ECI treatment and evaluation. After the initial surgery to remove the cancer, a series of vaccinations will follow. After the vaccinations, the personalized T cells are collected and activated. Following intravenous infusion of activated ‘killer’ T cells, there may be several follow-up evaluations.
ECI is a promising oncology treatment modality for canine cancer for several reasons: